IDOVEN receives €6.5 million of funding from the European Innovation Council

From IDOVEN we are very honoured and grateful to have been selected by the prestigious and highly selective EIC (European Innovation Council) Accelerator innovation programme.

EIC Accelerator is the European Commission's flagship programme for start-ups or SMEs, and was launched in September 2019 as part of the Horizon 2020 (H2020). The EIC Accelerator recognises Europe's most impactful and ground-breaking innovations, and offers support on a larger scale through funding, mentoring and access to the EIC network.

IDOVEN is one of 99 projects to be funded by EIC Accelerator in 2022, selected by a panel of experts from over 4,000 top-tier projects submitted across Europe.

With this funding milestone, IDOVEN is recognised as one of Europe's leading innovators in cardiology and digital healthcare.

The EIC's support brings us one step closer to scaling up Willem, our  Artificial Intelligence platform worldwide to prevent and diagnose cardiovascular disease. IDOVEN prevent and diagnose cardiovascular disease.

IDOVEN will receive funding of EUR 6.5 million and will use the funds to further invest in R&D, expand product offerings, hire key positions and drive growth in new markets.

According to Jean-Eric Paquet, the European Union's director general for research and innovation, "EIC should become Europe's unicorn factory". "We are creating possibly the largest DeepTech fund in Europe" with €10 billion, managed by the European Innovation Council (EIC), to support European projects.

"Thewhole team is proud and very grateful to have been selected by the EIC Accelerator, which supports IDOVEN's innovative technology based on the highest standards of scientific research and exceptional growth potential," said Dr. Manuel Marina Breysse, co-founder and CEO of IDOVEN.

"We have experienced tremendous growth and are collaborating with industry leaders to validate the power of our AI platform by seeking to increase diagnostic accuracy, help physicians reduce waiting lists, increase remote patient monitoring capabilities, accelerate drug development and improve economics across the healthcare system. With the ultimate goal of protecting lives and reducing the impact cardiovascular disease has on the world today.

En nombre de todo el equipo IDOVEN queremos dar las gracias a Evelio Jimeno, EJinnovation, Esther Casado, Luis Guerra, todos los asesores de CDTI, Ana Maiques, Andrea Barber, RatedPower Team, Seshu Ajjarapu, Jose Antonio Martinez Rubio, John Dunne, Nicolás López Polo, Pablo Martínez, EIT Health, Google for Startups, Fundación Iker Casillas, AI for Good, United Nations, Lilly, CNIC, Endeavor, CaixaBank, Fundación Innovación Bankinter, Barcelona Supercomputing Center, Stanford University, Universidad Politécnica de Madrid, Agencia Española para la protección de la Salud en el Deporte (AEPSAD), Fundación EverisMaría Thiscal López LluvaSpanish Society of Cardiology, Natalia Pinilla, Libin Cardiovascular Institute - University of CalgaryCentro de Investigación Biomédica en Red Enfermedades CardiovacularesMAESTRIA Consortium, nuestros inversores Wayra, Accel, nuestros Business Angels y todas las empresas, socios, amigos, familiares, clientes, hospitales, líderes de opinión, instituciones de investigación, pacientes y ciudadanos que nos están apoyando. Esperamos continuar enorgulleciéndolos al desarrollar nuestra ciencia e IA con los más altos estándares de calidad. Nos comprometemos a seguir haciendo nuestro trabajo con el nivel de detalle y cariño con el que lo hemos hecho hasta ahora. Gracias por vuestra confianza.

We're building the digital cardiology dream team and have just opened new positions to keep the team growing in sales, regulatory affairs, machine learning and data engineering, marketing and human resources. If you enjoy solving big challenges in healthcare or know talented people who want to help us prevent heart disease - the leading cause of death around the world - with #artificialintelligence follow us on LinkedIn or send us your CV to

We would love to meet you and talk about how we can make a difference together.

Recent articles

Read All

CB Insights has named Idoven as one of the 150 most promising private digital health companies of 2022.

Idoven's AI platform, a key ally for ICMs to improve arrhythmia and false positive detection.

AstraZeneca and Idoven are using Artificial Intelligence to diagnose cardiovascular diseases through a pioneering project in Europe